Outcomes of patients with relapsed low-grade lymphoma retreated with rituximab are similar to rituximab naïve patients

Rituximab combined with chemotherapy has been shown to be superior to chemotherapy alone in patients with relapsed/refractory indolent lymphomas [1–3]. However, these trials were conducted prior to...